Story perspectives

Novo's Oral Wegovy: Promising Weight Loss and Heart Health

9/19/2025

50 6

Summary

Story summary

Novo's oral Wegovy shows potential for weight loss and improved cardiovascular risk in obese patients, awaiting FDA approval.
The company filed for regulatory approval in April, with a decision anticipated in Q4 2025.
Following positive trial results, Novo's stock increased by over 7%.
Participants using oral Wegovy lost an average of 16.6% of body weight, surpassing the placebo group.
A trial of Ozempic demonstrated a 25% reduction in severe cardiovascular events among nearly 60,000 Medicare patients.

1 of 1

Story summary

Novo's oral Wegovy shows potential for weight loss and improved cardiovascular risk in obese patients, awaiting FDA approval.
The company filed for regulatory approval in April, with a decision anticipated in Q4 2025.
Following positive trial results, Novo's stock increased by over 7%.
Participants using oral Wegovy lost an average of 16.6% of body weight, surpassing the placebo group.
A trial of Ozempic demonstrated a 25% reduction in severe cardiovascular events among nearly 60,000 Medicare patients.